DK0922223T3 - Fremgangsmåde til prognosticering af cancer - Google Patents
Fremgangsmåde til prognosticering af cancerInfo
- Publication number
- DK0922223T3 DK0922223T3 DK97931170T DK97931170T DK0922223T3 DK 0922223 T3 DK0922223 T3 DK 0922223T3 DK 97931170 T DK97931170 T DK 97931170T DK 97931170 T DK97931170 T DK 97931170T DK 0922223 T3 DK0922223 T3 DK 0922223T3
- Authority
- DK
- Denmark
- Prior art keywords
- thymosin beta
- gene
- cancers
- seq
- members
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5759—Thymosin or related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/664,857 US5858681A (en) | 1996-06-17 | 1996-06-17 | Method for prognosis of prostate cancer |
PCT/US1997/010306 WO1997048982A1 (en) | 1996-06-17 | 1997-06-13 | A method for diagnosis and prognosis of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0922223T3 true DK0922223T3 (da) | 2003-07-14 |
Family
ID=24667736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97931170T DK0922223T3 (da) | 1996-06-17 | 1997-06-13 | Fremgangsmåde til prognosticering af cancer |
Country Status (11)
Country | Link |
---|---|
US (2) | US5858681A (de) |
EP (2) | EP0922223B1 (de) |
JP (1) | JP3642431B2 (de) |
AT (2) | ATE236406T1 (de) |
AU (1) | AU723144B2 (de) |
CA (1) | CA2257858A1 (de) |
DE (2) | DE69720471T2 (de) |
DK (1) | DK0922223T3 (de) |
ES (1) | ES2196345T3 (de) |
PT (1) | PT922223E (de) |
WO (1) | WO1997048982A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7951544B1 (en) | 1999-07-09 | 2011-05-31 | Sanford-Burnham Medical Research Institute | Method for determining the prognosis of cancer patients by measuring levels of bag expression |
US20020155514A1 (en) * | 2000-12-01 | 2002-10-24 | Hale Laura P. | Zinc alpha-2-glycoprotein as indicator of cancer |
US20050123925A1 (en) * | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
GR1004636B (el) * | 2001-11-28 | 2004-07-14 | Εθνικοακεντροαερευνασαφυσικωναεπιστημωνα}Εκεφεbα@Α@Δημοκριτος@Αα | Προγνωσηατουακαρκινουαμεαχρησηατησαθυμοσινησαβ@α}τβ@bαα |
WO2003071252A2 (en) | 2002-02-15 | 2003-08-28 | Exact Sciences Corporation | Methods for analysis of molecular events |
WO2004018678A1 (ja) | 2002-08-21 | 2004-03-04 | Takeda Pharmaceutical Company Limited | 癌の予防・治療剤 |
US20060105343A1 (en) * | 2003-01-09 | 2006-05-18 | Children's Medical Center Corporation | Methods for diagnosis and prognosis of cancer |
WO2006026654A2 (en) | 2004-08-27 | 2006-03-09 | Exact Sciences Corporation | Method for detecting a recombinant event |
US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
US8409794B2 (en) * | 2006-03-24 | 2013-04-02 | Phenomenome Discoveries Inc. | Biomarkers useful for diagnosing prostate cancer, and methods thereof |
US7449715B2 (en) * | 2006-04-06 | 2008-11-11 | Xerox Corporation | Poly[bis(ethynyl)heteroacene]s and electronic devices generated therefrom |
EP2081027A4 (de) | 2006-08-04 | 2009-09-23 | Ajinomoto Kk | Verfahren zur bewertung von lungenkrebs, lungenkrebsbewertungsvorrichtung, lungenkrebsbewertungsverfahren, lungenkrebsbewertungssystem, lungenkrebsbewertungsprogramm und aufzeichnungsmedium |
WO2008075662A1 (ja) | 2006-12-21 | 2008-06-26 | Ajinomoto Co., Inc. | 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体 |
WO2008075663A1 (ja) | 2006-12-21 | 2008-06-26 | Ajinomoto Co., Inc. | 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体 |
CN102066946B (zh) * | 2008-06-20 | 2016-08-31 | 味之素株式会社 | 前列腺疾病的评价方法 |
GB2476789A (en) * | 2009-11-10 | 2011-07-13 | Gl Holdings Inc Bv | Use of thymosin for treatment of type 2 diabetes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248591A (en) * | 1991-05-02 | 1993-09-28 | Puente Fernando D | Diagnosis of cancer and other proliferative disorders by analysis of prothymosin alpha expression |
-
1996
- 1996-06-17 US US08/664,857 patent/US5858681A/en not_active Expired - Fee Related
-
1997
- 1997-06-13 JP JP50316198A patent/JP3642431B2/ja not_active Expired - Fee Related
- 1997-06-13 WO PCT/US1997/010306 patent/WO1997048982A1/en active IP Right Grant
- 1997-06-13 AT AT97931170T patent/ATE236406T1/de not_active IP Right Cessation
- 1997-06-13 EP EP97931170A patent/EP0922223B1/de not_active Expired - Lifetime
- 1997-06-13 DE DE69720471T patent/DE69720471T2/de not_active Expired - Fee Related
- 1997-06-13 AT AT02020049T patent/ATE314652T1/de not_active IP Right Cessation
- 1997-06-13 CA CA002257858A patent/CA2257858A1/en not_active Abandoned
- 1997-06-13 DE DE69735020T patent/DE69735020T2/de not_active Expired - Fee Related
- 1997-06-13 PT PT97931170T patent/PT922223E/pt unknown
- 1997-06-13 AU AU34874/97A patent/AU723144B2/en not_active Ceased
- 1997-06-13 DK DK97931170T patent/DK0922223T3/da active
- 1997-06-13 ES ES97931170T patent/ES2196345T3/es not_active Expired - Lifetime
- 1997-06-13 EP EP02020049A patent/EP1270745B1/de not_active Expired - Lifetime
-
1998
- 1998-08-18 US US09/135,599 patent/US6150117A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1270745A3 (de) | 2004-06-09 |
US6150117A (en) | 2000-11-21 |
PT922223E (pt) | 2003-08-29 |
EP0922223B1 (de) | 2003-04-02 |
EP1270745B1 (de) | 2005-12-28 |
CA2257858A1 (en) | 1997-12-24 |
DE69735020T2 (de) | 2006-07-27 |
EP0922223A1 (de) | 1999-06-16 |
DE69720471D1 (de) | 2003-05-08 |
ATE314652T1 (de) | 2006-01-15 |
AU723144B2 (en) | 2000-08-17 |
ATE236406T1 (de) | 2003-04-15 |
DE69720471T2 (de) | 2004-02-19 |
JP3642431B2 (ja) | 2005-04-27 |
DE69735020D1 (de) | 2006-02-02 |
US5858681A (en) | 1999-01-12 |
ES2196345T3 (es) | 2003-12-16 |
EP1270745A2 (de) | 2003-01-02 |
JP2000513098A (ja) | 2000-10-03 |
WO1997048982A1 (en) | 1997-12-24 |
AU3487497A (en) | 1998-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0922223T3 (da) | Fremgangsmåde til prognosticering af cancer | |
Oien et al. | Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down‐regulated in gastric carcinoma, and shows high evolutionary conservation | |
US7858325B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
CA2328989A1 (en) | Serpentine transmembrane antigens expressed in human cancers and uses thereof | |
Kaname et al. | The expression of truncated MK in human tumors | |
Glynne‐Jones et al. | TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence | |
WO1996039516A2 (en) | Targets for breast cancer diagnosis and treatment | |
RU2001104349A (ru) | Композиции и способы для терапии и диагностики рака предстательной железы | |
CA2329137A1 (en) | Novel tumor antigen useful in diagnosis and therapy of prostrate and colon cancer | |
WO1999027098A3 (en) | A-33 related antigens and their pharmacological uses | |
ATE287952T1 (de) | Humanes thymosin beta 15 gen,protein und dessen verwendungen | |
EP1642906A3 (de) | Zusammensetzung und Verfahren zur Diagnose von Tumoren | |
AP2000001917A0 (en) | Gene encoding labyrinthin, a marker for cancer. | |
Wagener et al. | Binding of five monoclonal anti‐CEA antibodies with different epitope specifities to various carcinoma tissues | |
Ke et al. | Elevated expression of calcium‐binding protein p9Ka is associated with increasing malignant characteristics of rat prostate carcinoma cells | |
Ueyama et al. | Structure and expression of rat and mouse mRNAs for Zn-α2-glycoprotein | |
WO2000037640A3 (en) | Compositions and methods for the treatment of tumor | |
Wang et al. | Expression of a breast‐cancer‐associated protein (pS2) in human neuro‐endocrine tumours | |
Jin et al. | Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies | |
Meria et al. | Tumour-associated trypsin inhibitor and renal cell carcinoma | |
Öberg | Biological aspects of neuroendocrine gastro-enteropancreatic tumours | |
CA2347085A1 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
JP4058567B2 (ja) | Tsa305遺伝子 | |
Ohtsuki et al. | Immunohistochemical study on the nm23 gene product (NDP kinase) in oral squamous cell carcinoma | |
McKeehan et al. | Heparin-binding (fibroblast) growth factor/receptor gene expression in the prostate |